Immunogenicity of an Inactivated Vaccine against Influenza A (H1N1) pdm09 Virus in Diabetic Patients

DOI Web Site 18 References

Bibliographic Information

Other Title
  • 糖尿病患者におけるインフルエンザA（H1N1）pdm09ワクチンの免疫原性
  • トウニョウビョウ カンジャ ニ オケル インフルエンザ A(H1N1)pdm09 ワクチン ノ メンエキ ゲンセイ

Search this article

Abstract

Diabetic patients are particularly susceptible to influenza, and studies show that diabetic patients have higher morbidity and mortality rates, compared with people without diabetes. It is important to analyze the immunogenicity of influenza vaccines among diabetic patients. Forty-nine patients received the (A (H1N1) pdm09) vaccine twice. We finally analyzed 48 patients after excluding one who was suspected to have been infected. We calculated the geometric mean titer (GMT), mean fold rise (MFR), seroprotection proportion (SP), seroresponse proportion (SR), seroconversion proportion (SC), and analyzed the relationship between immunity and the prevaccination titer, the HbA1c and other parameters. After vaccination, the GMT increased in all categories, and the MFR in all patients increased by 5.3 after the first dose. An analysis of all of the patients showed that the SP after the first dose (S1) was 52 %, that after the second dose (S2) was 54 %, the SR S1 was 69 %, the S2 was 77 %, the SC S1 was 46 % and the S2 was 48 %. The MFR and SC met the standards of the European Agency for the Evaluation of Medical Products for Inducing Immunity. No significant relationship was found between the diabetic factors and the antibody response to the influenza A (H1N1) vaccine. These results suggest that advanced diabetic factors do not materially influence the immunogenicity of the influenza vaccine. Thus, it is reasonable to consider that influenza vaccination should be recommended for diabetic patients.<br>

Journal

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top